AzTrials
AzTrials

Innate ImmunityNCT03637894

Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery

A study testing Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants in people with Innate Immunity and Newborns, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed… Read more about this study

Who is it for?
Ages 1 day to 7 daysHealthy volunteers can take part
Conditions the study is for
Innate Immunity, Newborns, Nutrition
What is being tested?
Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
96 participants
Where
1 siteItaly
Study dates
26 Aug 2015to 21 Jun 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 7 days
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Full term healthy infants
  • Gestational age from 37 to 41 weeks
  • Weight appropriate for gestational age (from 10th to 90th centile according to World Health Organization chart)
  • Human milk not available or not possible

Who cannot join

  • Weight small for gestational age (< 10th centile) or large for gestational age (> 90th centile) according to World Health Organization chart
  • Congenital abnormalities, chromosomal, hearth, gastrointestinal, respiratory, neurological or metabolic disease.
  • Perinatal infections
  • Positive familiarity for milk proteins allergies

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Fondazione Ca' Granda Ospedale Maggiore Policlinico

    Milan, 20122

Other trials in Italy

About this study

This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed a standard formula (Plasmon Primigiorni), according to mode of delivery. Breastfed infants were the reference group.

Read the detailed description

The microbiota plays an important role in modulating the development of the immune system, making decisive the interrelation that between nutrition, microbiota and immune cells to modulate long-term health outcomes.

The type of feeding, especially breastfeeding, and the type of delivery are factors that can contribute to the development of the microbiota. Specifically, the exclusive breastfeeding promotes the development of bifidobacteria that promotes protection against potential infections and the development of the immune system.

In recent years it was improved the biological effects of formula milk, that represent the substitutes of breast milk when this is not available or if there are contraindications to breastfeeding. Functional foods derived from fermentation of cow's milk with probiotic strains have been proposed for the prevention of infectious diseases of the child. Recently, in a monocentric double-blind prospective study, the efficacy of fermented cow's milk with Lactobacillus paracasei CBA L74 was evaluated in the prevention of common winter infections in children aged between 12 and 48 months. In this study, children treated with fermented milk had a lower incidence of respiratory and gastrointestinal tract infections compared to the control group. This effect was associated with a significant stimulation of innate immunity (α- and β-defensin, LL-37) and acquired (secretory IgA) and to a modulation of composition and function of the intestinal microbiota characterized by a significant increase in strains producing butyric acid (Firmicutes phyla). The nutritional intervention was very well accepted by the children and no adverse events were observed.

Primary objectives of this study were:

To evaluate whether the feeding with a fermented formulated milk determines an increase in anti-microbial peptides such as catelecidine, alpha and beta defensin and secretory IgA compared to the feed with the standard formula (Plasmon Primigiorni), with reference to the mother's milk.

Secondary objective:

  • Value the tolerance in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
  • Value the modifications of the intestinal microbiota in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.

Study design: Single-center, randomized, double-blind, parallel group study with reference group.

Methods:

  • Evaluation of the anthropometric parameters (weight, length and cranial circumference)
  • Evaluation of body composition by plethysmography
  • Evaluation of the gastrointestinal tolerance of fermented formulated milk by means of data collection and diary delivery to the parents of the participants
  • Evaluation of the safety of fermented formulated milk by recording adverse events
  • Determination of faecal samples of antimicrobial peptides (defensins, catelecidines), IgA, microbiota and metabolome.

Infants will be enrolled at birth (within 7 days of life) upon acquisition of the informed consent of both parents.

At the time of enrollment, newborns who take breast milk due to the absence of breast milk will be randomized to receive up to the third month of age or a fermented formulated milk or a standard formula (Plasmon First Days).

Enrollment will be carried out by promoting and supporting breastfeeding and, in the event of exclusive breastfeeding forecasts for at least the first 3 months of age, newborns will be included in the study as a control group.

There are 3 medical visits to enrollment (V0), the first (V1) and the third month of life (V2).

During the visits the anthropometric parameters, the body composition, and the gastroenteric tolerance will be evaluated. A stool sample will also be collected at the three points of the life study in order to determine the anti-microbial peptides (catelecidine, alpha and beta defensin) and the secretory IgA, and perform the analysis of the microbiota and the metabolome.

Statistical analysis:

The sample size was determined to identify between the two groups of infants, the one that received the fermented formulated milk and the one that received standard formulated milk (Plasmon Primigiorni), a difference in the content of faecal α-defensins on samples of feces. Considering the results of the effect of a treatment with milk fermented with L. paracasei CBA L74 on fecal α-defensins in children attending preschool centers mean value (DS) vs placebo [4.8 (4.2) vs 1 (0.6), respectively] we calculated that 12 newborns are needed per group with a power of 84% and an alpha of 0.05. Assuming a 30% drop-out rate, at least 16 newborns per group must be recruited.

Criteria for the evaluation of variables The descriptive analyzes will be performed by calculating mean, median and standard deviations for the continuous variables and expressing the distribution of the frequencies for the discrete variables. The main analysis will resort to tests for independent samples, Student or Mann-Whitney tests according to the distribution of the outcome variables. To jointly analyze the trend in time from V0 to V2 of the outcome variables in the two groups, the one that received the fermented formulated milk and the one that received the standard formula, based on the type of delivery (spontaneous or cesarean) will be used regression models for repeated measurements (random effects models or GEE models).

Being tested
Feeding infants with fermented formula milk, Feeding infants with standard formula milk, Breastfeeding infants
Keywords
Newborns, Fermented milk, Innate immunity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Feeding infants with fermented formula milkDietary supplement

    Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

  • Feeding infants with standard formula milkOther

    Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

  • Breastfeeding infantsOther

    Reference group

Study groups in NCT03637894
Study groupRoleWhat they receive
Infants born by CS-fed fermented formulaActive comparatorFeeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
Receives: Dietary Supplement: Feeding infants with fermented formula milk
Infants born by CS-fed standard formulaPlacebo comparatorFeeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
Receives: Other: Feeding infants with standard formula milk
Infants born by CS-breastfedOtherInfants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section. The breastfeeding infants were the reference group
Receives: Other: Breastfeeding infants
Infants born by ED-fed fermented formulaActive comparatorFeeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
Receives: Dietary Supplement: Feeding infants with fermented formula milk
Infants born by ED-fed standard formulaPlacebo comparatorFeeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
Receives: Other: Feeding infants with standard formula milk
Infants born by ED-breastfedOtherInfants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life. The breastfeeding infants were the reference group.
Receives: Other: Breastfeeding infants

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline Innate immunity at 30 days of life and at 90 days of life.

    Fecal dosage of catelecidines, alfa and beta defensins and sIgA

    Measured: 0-7 days of life, at 30 days of life and at 90 days of life.

Secondary outcomes (6)
  1. Gastrointestinal tolerance

    Gastrointestinal tolerance was evaluated by the use of a daily diary computed by the parents to record vomiting/gaseous colics/stool frequency.

    Measured: 0-7 days of life, at 30 days of life and at 90 days of life.

  2. Weight

    weight (g)

    Measured: 0-7 days of life, at 30 days of life and at 90 days of life.

  3. Body composition

    Body composition assessment in term of fat mass and fat free mass by air displacement

    Measured: 0-7 days of life and at 90 days of life.

  4. Anthropometry

    length and head circumference (cm)

    Measured: 0-7 days of life, at 30 days of life and at 90 days of life.

  5. Microbiota

    gut microbiota assessment

    Measured: 0-7 days of life and at 90 days of life.

  6. Metabolomics

    stool metabolomic analysis

    Measured: 0-7 days of life and at 90 days of life.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Aug 2018
  2. Study start26 Aug 2015
  3. Primary completion21 Jun 2017
  4. Study completion21 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
RCT double blind study
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
96 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03637894
Sponsor's protocol ID
FERT15
Status last verified
Jan 2018
First submitted
11 Jan 2018
Last updated
20 Aug 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The individual participant data will not shared with other researchers.

Publications

  • Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nugnes R, Ferri P, Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017 Feb;36(1):118-125. doi: 10.1016/j.clnu.2015.12.004. Epub 2015 Dec 17.

    PubMed 26732025
  • Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, Rescigno M. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.

    PubMed 24520333
  • Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):147-52. doi: 10.1097/00005176-200408000-00004.

    PubMed 15269618
  • Indrio F, Ladisa G, Mautone A, Montagna O. Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatr Res. 2007 Jul;62(1):98-100. doi: 10.1203/pdr.0b013e31806772d3.

    PubMed 17515847
  • Roggero P, Liotto N, Pozzi C, Braga D, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocerino R, Budelli A, Mosca F, Rescigno M. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. Nat Commun. 2020 Jun 1;11(1):2703. doi: 10.1038/s41467-020-16582-1.

    PubMed 32483147

Questions about this trial

What is this clinical trial studying?

A study testing Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants in people with Innate Immunity and Newborns, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline Innate immunity at 30 days of life and at 90 days of life. (time frame: 0-7 days of life, at 30 days of life and at 90 days of life.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03637894, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in